Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting

Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)

Related Keywords

Delaware ,United States ,Japan ,American ,Dennis Riedl ,Catalina Loveman ,Christine Chiou ,Hidradenitis Suppurativa ,Jim Lee ,Drug Administration ,Group Vice ,Exchange Commission ,Us Food Drug Administration ,American Academy Of Dermatology ,Maruho Co Ltd ,Incyte Corporation ,Journal Of The American Academy Dermatology ,Annual Meeting ,Group Vice President ,Inflammation Autoimmunity ,Clinical Response ,Randomized Withdrawal Arm ,Ev Long Term Extension Phase ,Ruxolitinib Cream ,Breaking Research ,Ruxolitinib Cream Treatment ,Open Label Arm ,Dose Ranging Study ,Symptom Control ,Atopic Dermatitis ,Pooled Analysis ,Long Term Safety Periods ,Two Phase ,Draining Tunnel ,Immunodermatology Blistering ,Noticeability Scale Score Maintenance ,Shift During ,Ev Phase ,Pigmentary Disorders ,Vitiligo Area Scoring Index Response Maintenance ,American Academy ,Versus Host Disease ,Ruxolitinib Treatment ,Dermatologic Manifestations ,Chronic Graft Versus Host Disease ,Post Hoc Analysis ,Immunodermatology Blistering Disorders ,Pigmentary Disorders Vitiligo ,Emergent Adverse Events ,Janus Kinase Inhibitors ,Patient Perspective ,Treating Vitiligo ,Person Event ,Multiple ,Abstracts ,Rom ,Incyte ,Rowing ,Ermatology ,Portfolio ,Featured ,Academy ,Nnual ,Meeting ,